Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 71

1.

Sequential combination of bortezomib and WEE1 inhibitor, MK-1775, induced apoptosis in multiple myeloma cell lines.

Barbosa RSS, Dantonio PM, Guimarães T, de Oliveira MB, Fook Alves VL, Sandes AF, Fernando RC, Colleoni GWB.

Biochem Biophys Res Commun. 2019 Nov 12;519(3):597-604. doi: 10.1016/j.bbrc.2019.08.163. Epub 2019 Sep 17.

PMID:
31540690
2.

Stew in its Own Juice: Protein Homeostasis Machinery Inhibition Reduces Cell Viability in Multiple Myeloma Cell Lines.

de Oliveira MB, Sanson LFG, Eugenio AIP, Barbosa-Dantas RSS, Colleoni GWB.

Curr Mol Med. 2019;19(2):112-119. doi: 10.2174/1566524019666190305134441.

PMID:
30834832
3.

Transcriptome Analysis of Mesenchymal Stem Cells from Multiple Myeloma Patients Reveals Downregulation of Genes Involved in Cell Cycle Progression, Immune Response, and Bone Metabolism.

Fernando RC, Mazzotti DR, Azevedo H, Sandes AF, Rizzatti EG, de Oliveira MB, Alves VLF, Eugênio AIP, de Carvalho F, Dalboni MA, Martins DC, Colleoni GWB.

Sci Rep. 2019 Jan 31;9(1):1056. doi: 10.1038/s41598-018-38314-8.

4.

Targeting the polarization of tumor-associated macrophages and modulating mir-155 expression might be a new approach to treat diffuse large B-cell lymphoma of the elderly.

Poles WA, Nishi EE, de Oliveira MB, Eugênio AIP, de Andrade TA, Campos AHFM, de Campos RR Jr, Vassallo J, Alves AC, Scapulatempo Neto C, Paes RAP, Landman G, Zerbini MCN, Colleoni GWB.

Cancer Immunol Immunother. 2019 Feb;68(2):269-282. doi: 10.1007/s00262-018-2273-2. Epub 2018 Nov 14.

PMID:
30430204
5.

Proteasome and heat shock protein 70 (HSP70) inhibitors as therapeutic alternative in multiple myeloma.

Eugênio AIP, Fook-Alves VL, de Oliveira MB, Fernando RC, Zanatta DB, Strauss BE, Silva MRR, Porcionatto MA, Colleoni GWB.

Oncotarget. 2017 Dec 1;8(70):114698-114709. doi: 10.18632/oncotarget.22815. eCollection 2017 Dec 29.

6.

Anti-myeloma effects of ruxolitinib combined with bortezomib and lenalidomide: A rationale for JAK/STAT pathway inhibition in myeloma patients.

de Oliveira MB, Fook-Alves VL, Eugenio AIP, Fernando RC, Sanson LFG, de Carvalho MF, Braga WMT, Davies FE, Colleoni GWB.

Cancer Lett. 2017 Sep 10;403:206-215. doi: 10.1016/j.canlet.2017.06.016. Epub 2017 Jun 20.

PMID:
28645562
7.

Efficacy and safety of bortezomib, thalidomide, and lenalidomide in multiple myeloma: An overview of systematic reviews with meta-analyses.

Aguiar PM, de Mendonça Lima T, Colleoni GWB, Storpirtis S.

Crit Rev Oncol Hematol. 2017 May;113:195-212. doi: 10.1016/j.critrevonc.2017.03.014. Epub 2017 Mar 16. Review.

PMID:
28427509
8.

Plasma cell leukemia with t(11;14)(q13;q32) simulating lymphoplasmacytic lymphoma - a diagnostic challenge solved by flow cytometry.

Loureiro AD, Gonçalves MV, Ikoma MR, Silva MR, Colleoni GW, Chauffaille ML, Yamamoto M.

Rev Bras Hematol Hemoter. 2017 Jan - Mar;39(1):66-69. doi: 10.1016/j.bjhh.2016.10.001. Epub 2016 Dec 22. No abstract available.

9.

Association of VEGFA-2578 C>A polymorphism with clinicopathological aspects and outcome in follicular lymphoma patients.

de Mendonça GR, Brito AB, Rocha RM, Delamain MT, de Andrade Natal R, Soares FA, Colleoni GW, Souza CA, Vassallo J, Lima CS.

Blood Cancer J. 2016 Aug 26;6(8):e464. doi: 10.1038/bcj.2016.76. No abstract available.

10.

TP53 Regulated Inhibitor of Apoptosis 1 (TRIAP1) stable silencing increases late apoptosis by upregulation of caspase 9 and APAF1 in RPMI8226 multiple myeloma cell line.

Fook-Alves VL, de Oliveira MB, Zanatta DB, Strauss BE, Colleoni GW.

Biochim Biophys Acta. 2016 Jun;1862(6):1105-10. doi: 10.1016/j.bbadis.2016.03.011. Epub 2016 Mar 24.

11.

Multiple myeloma cell lines and primary tumors proteoma: protein biosynthesis and immune system as potential therapeutic targets.

Fernando RC, de Carvalho F, Mazzotti DR, Evangelista AF, Braga WMT, de Lourdes Chauffaille M, Leme AFP, Colleoni GWB.

Genes Cancer. 2015 Nov;6(11-12):462-471.

12.

Angiomirs expression profiling in diffuse large B-Cell lymphoma.

Borges NM, do Vale Elias M, Fook-Alves VL, Andrade TA, de Conti ML, Macedo MP, Begnami MD, Campos AH, Etto LY, Bortoluzzo AB, Alves AC, Young KH, Colleoni GW.

Oncotarget. 2016 Jan 26;7(4):4806-16. doi: 10.18632/oncotarget.6624.

13.

A microRNA signature profile in EBV+ diffuse large B-cell lymphoma of the elderly.

Andrade TA, Evangelista AF, Campos AH, Poles WA, Borges NM, Camillo CM, Soares FA, Vassallo J, Paes RP, Zerbini MC, Scapulatempo C, Alves AC, Young KH, Colleoni GW.

Oncotarget. 2014 Dec 15;5(23):11813-26.

14.

FOXP3 and CTLA4 overexpression in multiple myeloma bone marrow as a sign of accumulation of CD4(+) T regulatory cells.

Braga WM, da Silva BR, de Carvalho AC, Maekawa YH, Bortoluzzo AB, Rizzatti EG, Atanackovic D, Colleoni GW.

Cancer Immunol Immunother. 2014 Nov;63(11):1189-97. doi: 10.1007/s00262-014-1589-9. Epub 2014 Aug 7.

15.

Is there any relationship between gene expression of tumor antigens and CD4+ T cells in multiple myeloma?

Braga WM, da Silva BR, Alves VL, Bortoluzo AB, Atanackovic D, Colleoni GW.

Immunotherapy. 2014;6(5):569-75. doi: 10.2217/imt.14.24.

PMID:
24896625
16.

Understanding myeloma cancer stem cells.

Pascutti F, Cunha LL, Rizzatti EG, Colleoni GW.

Immunotherapy. 2013 Dec;5(12):1291-4. doi: 10.2217/imt.13.132. No abstract available.

PMID:
24283839
17.

Activation of the Janus kinase/signal transducer and activator of transcription pathway in multiple myeloma is not related to point mutations in kinase and pseudokinase domains of JAK1.

Corbi FC, de Oliveira MB, Morelli VM, Han SW, Renauld JC, Knoops L, Colleoni GW.

Leuk Lymphoma. 2014 May;55(5):1176-80. doi: 10.3109/10428194.2013.828352. Epub 2013 Sep 3.

PMID:
23885837
18.

Serum free light chains and post-transplant lymphoproliferative disorder in patients with renal transplant.

Fernando RC, Rizzatti EG, Braga WM, Santos MG, de Oliveira MB, Pestana JO, Baiocchi OC, Colleoni GW.

Leuk Lymphoma. 2013 Oct;54(10):2177-80. doi: 10.3109/10428194.2013.764423. Epub 2013 Mar 4.

PMID:
23398208
19.

MAGE-C1/CT7 and MAGE-C2/CT10 are frequently expressed in multiple myeloma and can be explored in combined immunotherapy for this malignancy.

de Carvalho F, Alves VL, Braga WM, Xavier CV Jr, Colleoni GW.

Cancer Immunol Immunother. 2013 Jan;62(1):191-5. doi: 10.1007/s00262-012-1376-4. Epub 2012 Nov 22.

PMID:
23180015
20.

Cancer/testis antigens expression and autologous serological response in a set of Brazilian non-Hodgkin's lymphoma patients.

Inaoka RJ, Jungbluth AA, Gnjatic S, Ritter E, Hanson NC, Frosina D, Tassello J, Etto LY, Bortoluzzo AB, Alves AC, Colleoni GW.

Cancer Immunol Immunother. 2012 Dec;61(12):2207-14. doi: 10.1007/s00262-012-1285-6. Epub 2012 May 26.

PMID:
22638551
21.

The role of regulatory T cells and TH17 cells in multiple myeloma.

Braga WM, Atanackovic D, Colleoni GW.

Clin Dev Immunol. 2012;2012:293479. doi: 10.1155/2012/293479. Epub 2012 Mar 27. Review.

22.

Cancer/Testis Antigen MAGE-C1/CT7: new target for multiple myeloma therapy.

de Carvalho F, Vettore AL, Colleoni GW.

Clin Dev Immunol. 2012;2012:257695. doi: 10.1155/2012/257695. Epub 2012 Mar 11. Review.

23.

Targeting MAGE-C1/CT7 expression increases cell sensitivity to the proteasome inhibitor bortezomib in multiple myeloma cell lines.

de Carvalho F, Costa ET, Camargo AA, Gregorio JC, Masotti C, Andrade VC, Strauss BE, Caballero OL, Atanackovic D, Colleoni GW.

PLoS One. 2011;6(11):e27707. doi: 10.1371/journal.pone.0027707. Epub 2011 Nov 16.

24.

Autologous stem cell transplantation improves quality of life in economically challenged, Brazilian multiple myeloma patients.

Etto LY, Morelli VM, Silva VC, Hungria VT, Ciconelli RM, Almeida MS, Oliveira JS, Barros JC, Durie BG, Colleoni GW.

Clinics (Sao Paulo). 2011;66(11):1855-9.

25.

An overview of cancer/testis antigens expression in classical Hodgkin's lymphoma (cHL) identifies MAGE-A family and MAGE-C1 as the most frequently expressed antigens in a set of Brazilian cHL patients.

Inaoka RJ, Jungbluth AA, Baiocchi OC, Assis MC, Hanson NC, Frosina D, Tassello J, Bortoluzzo AB, Alves AC, Colleoni GW.

BMC Cancer. 2011 Sep 28;11(1):416.

26.

Evaluation of LAGE-1 and NY-ESO-1 expression in multiple myeloma patients to explore possible benefits of their homology for immunotherapy.

de Carvalho F, Vettore AL, Inaoka RJ, Karia B, Andrade VC, Gnjatic S, Jungbluth AA, Colleoni GW.

Cancer Immun. 2011 Jan 20;11:1.

27.

Number of expressed cancer/testis antigens identifies focal adhesion pathway genes as possible targets for multiple myeloma therapy.

Andrade VC, Vettore AL, Panepucci RA, Almeida MS, Yamamoto M, De Carvalho F, Caballero OL, Zago MA, Colleoni GW.

Leuk Lymphoma. 2010 Aug;51(8):1543-9. doi: 10.3109/10428194.2010.491136.

PMID:
20528248
28.

Comparative expression of a set of genes to an internal housekeeping control in CDNA amplified and not amplified by PolyAPCR in non-Hodgkin's lymphoma samples obtained from fine-needle aspiration cytology.

Corbi FC, Inaoka RJ, Felix RS, Andrade VC, Etto LY, Vettore AL, Franco MF, Colleoni GW.

Diagn Mol Pathol. 2010 Mar;19(1):40-4. doi: 10.1097/PDM.0b013e3181b0b618.

PMID:
20186011
29.

Proangiogenic cytokines produced by non-Hodgkin lymphoma tumor cells induce angiogenesis in infiltrated bone marrow samples.

Etto LY, Silva MR, Dalboni MA, Alves AC, Colleoni GW.

Leuk Lymphoma. 2009 Aug;50(8):1381-3. doi: 10.1080/10428190903039982. No abstract available.

PMID:
19593697
30.

Expression of eight genes of nuclear factor-kappa B pathway in multiple myeloma using bone marrow aspirates obtained at diagnosis.

Sampaio MS, Vettore AL, Yamamoto M, Chauffaille Mde L, Zago MA, Colleoni GW.

Histol Histopathol. 2009 Aug;24(8):991-7. doi: 10.14670/HH-24.991.

PMID:
19554506
31.

TGFbetaR2 aberrant methylation is a potential prognostic marker and therapeutic target in multiple myeloma.

de Carvalho F, Colleoni GW, Almeida MS, Carvalho AL, Vettore AL.

Int J Cancer. 2009 Oct 15;125(8):1985-91. doi: 10.1002/ijc.24431.

32.

Frequency and prognostic relevance of cancer testis antigen 45 expression in multiple myeloma.

Andrade VC, Vettore AL, Regis Silva MR, Felix RS, Almeida MS, de Carvalho F, Zago MA, Caballero OL, Simpson AJ, Colleoni GW.

Exp Hematol. 2009 Apr;37(4):446-9. doi: 10.1016/j.exphem.2008.12.003. Epub 2009 Feb 10.

PMID:
19211183
33.

SAGE analysis highlights the importance of p53csv, ddx5, mapkapk2 and ranbp2 to multiple myeloma tumorigenesis.

Felix RS, Colleoni GW, Caballero OL, Yamamoto M, Almeida MS, Andrade VC, Chauffaille Mde L, Silva WA Jr, Begnami MD, Soares FA, Simpson AJ, Zago MA, Vettore AL.

Cancer Lett. 2009 Jun 8;278(1):41-8. doi: 10.1016/j.canlet.2008.12.022. Epub 2009 Jan 25.

PMID:
19171422
34.

Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study.

Young KH, Leroy K, Møller MB, Colleoni GW, Sánchez-Beato M, Kerbauy FR, Haioun C, Eickhoff JC, Young AH, Gaulard P, Piris MA, Oberley TD, Rehrauer WM, Kahl BS, Malter JS, Campo E, Delabie J, Gascoyne RD, Rosenwald A, Rimsza L, Huang J, Braziel RM, Jaffe ES, Wilson WH, Staudt LM, Vose JM, Chan WC, Weisenburger DD, Greiner TC.

Blood. 2008 Oct 15;112(8):3088-98. doi: 10.1182/blood-2008-01-129783. Epub 2008 Jun 17.

35.

Confirmation of the utility of the International Staging System and identification of a unique pattern of disease in Brazilian patients with multiple myeloma.

Hungria VT, Maiolino A, Martinez G, Colleoni GW, Coelho EO, Rocha L, Nunes R, Bittencourt R, Oliveira LC, Faria RM, Pasquini R, Magalhães SM, Souza CA, Pinto Neto JV, Barreto L, Andrade E, Portella Mdo S, Bolejack V, Durie BG; International Myeloma Working Group Latin America.

Haematologica. 2008 May;93(5):791-2. doi: 10.3324/haematol.11637. No abstract available.

36.

Prognostic impact of cancer/testis antigen expression in advanced stage multiple myeloma patients.

Andrade VC, Vettore AL, Felix RS, Almeida MS, Carvalho F, Oliveira JS, Chauffaille ML, Andriolo A, Caballero OL, Zago MA, Colleoni GW.

Cancer Immun. 2008 Feb 1;8:2.

37.

Is the follicular lymphoma international prognostic index better than the international prognostic index to identify high-risk follicular lymphoma patients?

Etto LY, Silva VC, Inaoka RJ, Costa RP, Alves AC, Colleoni GW.

Leuk Lymphoma. 2007 Mar;48(3):526-30.

PMID:
17454593
38.

Essential thrombocythemia after treatment of non-Hodgkin's lymphoma.

Maciel JF, de Lourdes Chauffaille M, Inaoka RJ, Colleoni GW, Yamamoto M.

Leuk Res. 2007 Nov;31(11):1593-5. Epub 2007 Feb 26. No abstract available.

PMID:
17324461
39.

Analysis of polymorphism at site -174 G/C of interleukin-6 promoter region in multiple myeloma.

Duch CR, Figueiredo MS, Ribas C, Almeida MS, Colleoni GW, Bordin JO.

Braz J Med Biol Res. 2007 Feb;40(2):265-7.

40.

Physical interaction of two cancer-testis antigens, MAGE-C1 (CT7) and NY-ESO-1 (CT6).

Cho HJ, Caballero OL, Gnjatic S, Andrade VC, Colleoni GW, Vettore AL, Outtz HH, Fortunato S, Altorki N, Ferrera CA, Chua R, Jungbluth AA, Chen YT, Old LJ, Simpson AJ.

Cancer Immun. 2006 Dec 1;6:12.

41.

Psychosocial adaptation and quality of life among Brazilian patients with different hematological malignancies.

Santos FR, Kozasa EH, Chauffaille Mde L, Colleoni GW, Leite JR.

J Psychosom Res. 2006 May;60(5):505-11.

PMID:
16650591
42.

Cutaneous T-cell lymphoma with HTLV-I infection: clinical overlap with adult T-cell leukemia/lymphoma.

Sakamoto FH, Colleoni GW, Teixeira SP, Yamamoto M, Michalany NS, Almeida FA, Chiba AK, Petri V, Fernandes MA, Pombo-de-Oliveira MS.

Int J Dermatol. 2006 Apr;45(4):447-9.

PMID:
16650175
43.

Plasmablastic multiple myeloma is associated with increased vascular endothelial growth factor immunoexpression.

Ribas C, Colleoni GW, Almeida MS, Aguiar KC, Silva MR, Bordin JO.

Braz J Med Biol Res. 2005 Nov;38(11):1609-13. Epub 2005 Oct 26.

44.

Epstein-Barr viral load, interleukin-6 and interleukin-10 levels in post-transplant lymphoproliferative disease: a nested case-control study in a renal transplant cohort.

Baiocchi OC, Colleoni GW, Caballero OL, Vettore AL, Bulgarelli A, Dalbone MA, Granato CF, Franco MF, Pestana JO.

Leuk Lymphoma. 2005 Apr;46(4):533-9.

PMID:
16019481
45.

p16 gene methylation lacks correlation with angiogenesis and prognosis in multiple myeloma.

Ribas C, Colleoni GW, Felix RS, Regis Silva MR, Caballero OL, Brait M, Bordin JO.

Cancer Lett. 2005 May 26;222(2):247-54. Epub 2004 Nov 11.

PMID:
15863274
46.
47.

Detection and possible prognostic relevance of p53 gene mutations in diffuse large B-cell lymphoma. An analysis of 51 cases and review of the literature.

Kerbauy FR, Colleoni GW, Saad ST, Regis Silva MR, Correa Alves A, Aguiar KC, Albuquerque DM, Kobarg J, Seixas MT, Kerbauy J.

Leuk Lymphoma. 2004 Oct;45(10):2071-8.

PMID:
15370252
48.

Bilateral central retinal vein occlusion associated with multiple myeloma.

Aggio FB, Cariello AJ, Almeida MS, Rodrigues CA, De Moraes NS, Colleoni GW, Farah ME.

Ophthalmologica. 2004 Jul-Aug;218(4):283-7.

PMID:
15258420
49.

Possible influence of clinical stage and type of treatment in the persistence of residual circulating t(14;18)-positive cells in follicular lymphoma patients.

Colleoni GW, Duarte LC, Kerbauy FR, Noguti MA, Felix RS, De Oliveira JS, Figueiredo MS, Alves AC.

Leuk Lymphoma. 2004 Mar;45(3):539-45.

PMID:
15160916
50.

Molecular analysis of gastric washings in the diagnosis and monitoring of gastric lymphomas.

Chen B, Colleoni GW, Salazar PA, Lal P, Gerdes H, Filippa DA.

Hum Pathol. 2004 May;35(5):582-6.

PMID:
15138933

Supplemental Content

Loading ...
Support Center